PCIA
BMY icon

Prime Capital Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Prime Capital Investment Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.57M Buy
25,903
+817
+3% +$47.6K 0.02% 401
2025
Q4 		$1.35M Sell
25,086
-1,575
-6% -$75.8K 0.02% 430
2025
Q3 		$1.2M Sell
26,661
-1,111
-4% -$51.9K 0.02% 443
2025
Q2 		$1.29M Sell
27,772
-12,306
-31% -$604K 0.02% 420
2025
Q1 		$2.44M Buy
40,078
+7,481
+23% +$436K 0.03% 330
2024
Q4 		$1.84M Buy
32,597
+1,429
+5% +$79.8K 0.03% 319
2024
Q3 		$1.61M Sell
31,168
-1,991
-6% -$93.4K 0.02% 349
2024
Q2 		$1.38M Sell
33,159
-12,949
-28% -$579K 0.02% 374
2024
Q1 		$2.5M Sell
46,108
-5,623
-11% -$286K 0.03% 307
2023
Q4 		$2.65M Sell
51,731
-1,311
-2% -$68.8K 0.04% 291
2023
Q3 		$3.08M Sell
53,042
-3,244
-6% -$199K 0.06% 210
2023
Q2 		$3.6M Buy
56,286
+7,841
+16% +$526K 0.07% 198
2023
Q1 		$3.36M Buy
48,445
+32,194
+198% +$2.27M 0.14% 129
2022
Q4 		$1.17M Buy
16,251
+4,335
+36% +$327K 0.04% 226
2022
Q3 		$847K Buy
11,916
+3,716
+45% +$270K 0.05% 188
2022
Q2 		$631K Buy
+8,200
New +$625K 0.04% 205
2021
Q3 		– Sell
-3,545
Closed -$237K – 305
2021
Q2 		$237K Buy
3,545
+1,132
+47% +$73.8K 0.01% 336
2021
Q1 		$152K Sell
2,413
-126
-5% -$7.84K 0.01% 262
2020
Q4 		$157K Sell
2,539
-45,144
-95% -$2.78M 0.01% 247
2020
Q3 		$2.88M Buy
47,683
+15,941
+50% +$959K 0.24% 85
2020
Q2 		$1.87M Sell
31,742
-19,671
-38% -$1.18M 0.17% 106
2020
Q1 		$2.87M Buy
51,413
+18,823
+58% +$1.15M 0.34% 58
2019
Q4 		$2.09M Buy
32,590
+31,873
+4,445% +$1.83M 0.24% 96
2019
Q3 		$36K Sell
717
-93,393
-99% -$4.39M 0.01% 334
2019
Q2 		$4.27M Buy
94,110
+31,364
+50% +$1.46M 0.78% 35
2019
Q1 		$2.99M Buy
62,746
+62,423
+19,326% +$3.11M 0.87% 33
2018
Q4 		$17K Buy
323
+183
+131% +$9.83K 0.01% 224
2018
Q3 		$9K Sell
140
-660
-83% -$39.2K ﹤0.01% 240
2018
Q2 		$44K Buy
800
+300
+60% +$16.2K 0.02% 205
2018
Q1 		$32K Buy
+500
New +$32.2K 0.02% 175

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prime Capital Investment Advisors's BMY Position: Q1 2026 in Review

Prime Capital Investment Advisors increased its Bristol-Myers Squibb (BMY) stake by 3.3% in Q1 2026, buying an estimated $47.6K and bringing the position to 25,903 shares worth $1.57M. The position accounts for 0.02% of the portfolio, ranked #401.

Prime Capital Investment Advisors first reported a position in BMY in Q1 2018 and has held it in 30 quarters since. The position peaked at $4.27M in Q2 2019. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Prime Capital Investment Advisors held 25,903 shares of Bristol-Myers Squibb worth $1.57M as of Q1 2026.
  • Prime Capital Investment Advisors bought 817 Bristol-Myers Squibb shares in Q1 2026, an estimated $47.6K.
  • Bristol-Myers Squibb made up 0.02% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #401 holding.
  • Prime Capital Investment Advisors first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 30 quarters since.
  • Prime Capital Investment Advisors's Bristol-Myers Squibb position peaked at $4.27M in Q2 2019.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.